Skip to main content
. 2018 May 22;9(39):25557–25571. doi: 10.18632/oncotarget.25374

Table 4. Top 10 hypo-methylated DNA methylated regions based on 10% difference between Cancer and Control (-1000 ≤ distance to transcription start site [TSS] ≤ +1000 base-pair DNA).

Gene Regions DMR location Distance To TSS Methylation Difference Gene Name or role
Start End % p q
SLC2A3 Intron 8,087,820 8,087,905 988 -61.18 1.06E-13 6.23E-12 Glucose transmembrane transporter activity
LOC338817 Promoter 11,700,194 11,700,609 -355 -55.46 1.36E-18 3.92E-16 N/A
MLH3 Promoter 75,518,893 75,518,943 -659 -51.32 2.22E-07 1.73E-06 DNA Mismatch Repair (MMR)
LRRC27 Promoter 134,144,308 134,144,429 951 -49.30 1.06E-08 1.32E-07 Leucine Rich Repeat Containing 27
FANCG Promoter 35,080,807 35,080,913 -795 -48.79 2.24E-08 2.51E-07 DNA Double-Strand Break Repair
RPSA Intron 39,450,361 39,450,501 481 -46.51 1.53E-07 1.27E-06 RNA binding, structural constituent of ribosome
SLC2A1 Promoter 43,425,368 43,425,715 -522 -44.71 8.39E-10 1.51E-08 Glucose transmembrane transporter activity
ZFP36 CDS 39,899,297 39,899,354 965 -43.30 2.97E-06 1.56E-05 DNA binding, RNA binding, Protein binding
HMHA1 Intron 1,077,542 1,077,680 911 -42.82 3.24E-12 1.23E-10 Minor histocompatibility protein HA-1
ARID5B Utr5 63,808,928 63,809,171 0 -42.54 6.81E-07 4.50E-06 FTO Obesity Variant Mechanism

Note: CDS: coding DNA sequence.